Additional file 1 of Discovery of small molecules with anthelmintic potential in the Medicines for Malaria Venture’s COVID and Global Health Priority Boxes using an infrared-based assay for Caenorhabditis elegans motility

Additional file 1: Additional Table 1. Primary screen activities of the 400 compounds in the MMV COVID and Global Health Priority Boxes. Compounds were tested at 40 µM for modulation of C. elegans motility after 24 h. Relative to DMSO control, the degree to which worm motility was decreased was characterized as a hit if < 25%. One (Global Health Priority Box (GHPB)) or two assays (COVID Box) in triplicate was performed. P-values were calculated using a one-sample t-test for the hit compounds only.